Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

136 results about "Malignant cells" patented technology

Malignant cells are abnormal cells associated with cancer. They are sometimes referred to as neoplastic cells and they may be found as part of a tumor such as a melanoma, or diffusely spread as displayed in leukemia.

Multi-omics pathological analysis system and method for colorectal cancer liver metastasis risk prediction

The invention discloses a multi-omics pathological analysis system and method for colorectal cancer liver metastasis risk prediction, and relates to the technical field of biomedicine and cancer diagnosis, the system comprises a data acquisition module, a data preprocessing module, a cell analysis module, a score construction module, a model construction and training module and a prediction and evaluation module; according to the method, multiple omics data including the single cell data set, the space transcriptome data, the batch RNA-seq data, the clinical data and the full slice image WSIs are integrated, comprehensive and accurate prediction of the colorectal cancer liver metastasis risk is achieved, cross-dimensional data fusion and analysis improve the prediction accuracy and reliability, and the risk of the colorectal cancer liver metastasis is reduced. The invention also provides a powerful tool for deeply exploring the molecular mechanism of tumorigenesis, development and metastasis, and particularly in a cell analysis module, cell subtypes and molecular characteristics closely related to liver metastasis can be disclosed by identifying and analyzing malignant cell subgroups LMTMCs triggering liver metastasis, so that the liver metastasis can be discovered. And a scientific basis is provided for formulating a personalized treatment scheme.
Owner:SOUTHWEST MEDICAL UNIV

Bispecific antibodies targeting CD47 and PD-L1 and methods of use thereof

This disclosure provides novel bispecific antibodies that specifically bind to CD47 and Programmed Death-Ligand 1 (PD-L1). The disclosure further relates to methods of making the bispecific antibodies and nucleic acids encoding the antibodies. The disclosure further relates to therapeutic methods for use of the bispecific antibodies in the treatment of a condition associated with malignant cells expressing CD47 and / or PD-L1.
Owner:NOVIMMUNE SA

Radioimmunoconjugates targeting phosphatidylserine for use in the treatment of cancer

Methods for treating cancers and precancerous conditions by administering an effective amount of a radiolabeled agent that targets cell surface phosphatidylserine, alone or in combination with other therapies, are provided. The radiolabeled phosphatidylserine targeting agent delivers radiation to cells that externally present phosphatidylserine, such as tumor cells, depleting those cells and neighboring malignant cells to effect overall tumor reduction. Radiation delivered by the radiolabeled phosphatidylserine targeting agent itself increases the cell surface expression of phosphatidylserine, leading to a feed-forward mechanism that drives further accumulation of the phosphatidylserine targeting agent at target lesions to enhance its therapeutic effect.
Owner:ACTINIUM PHARMACEUTICALS INC

Bispecific chimeric antigen receptor targeting CD117 and CD7 and its application

The present invention relates to a bispecific chimeric antigen receptor targeting CD117 and CD7 and its application, wherein the bispecific chimeric antigen receptor comprises a signal peptide, an antigen binding domain, a hinge region, a transmembrane domain and a signal transduction domain, wherein the antigen binding domain comprises a CD117 binding domain and a CD7 binding domain. The bispecific chimeric antigen receptor provided by the present invention combines targeted antibodies for CD117 and CD7 together, recognizes and binds to two different antigens at the same time, enhances the targeted elimination ability of malignant cells, and by acting on hematopoietic stem cells and immune cells at the same time, can more effectively eliminate tumor cells in the receptor, while retaining or reconstructing normal hematopoietic and immune functions.
Owner:GUANGZHOU BIO GENE TECH CO LTD

B-cell lymphoma early diagnosis marker, cross-species screening method based on lamprey and application

The invention discloses an early diagnosis marker for B-cell lymphoma, a cross-species screening method based on lamprey and application, and relates to the technical field of molecular diagnosis. In the prior art, tissue biopsy is strong in invasiveness, and a traditional marker is low in early detection rate; in order to solve the problems that a large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large- When the expression quantity of the gene in a sample is greater than or equal to 1.8 times of that of a normal B cell (HMY2. CIR), the lymphoma is judged to be positive, and the minimally invasive early diagnosis efficiency is remarkably improved.
Owner:LIAONING NORMAL UNIVERSITY

Method and device for identifying malignant cells

The invention provides a malignant cell identification method and device, and the method comprises the steps: obtaining a to-be-detected specimen image which is acquired based on a rapid on-site evaluation technology; the to-be-detected sample image is input into a malignant cell recognition model, a malignant cell recognition result output by the malignant cell recognition model is obtained, and the malignant cell recognition result comprises the number of malignant cells included in the to-be-detected sample image and the position of each malignant cell in the to-be-detected sample image; the malignant cell identification model is obtained by training an initial malignant cell identification model based on a data enhanced sample set, and the real label of a sample image in the data enhanced sample set is the real number of malignant cells and the real position of each malignant cell included in a target sample image; the initial malignant cell recognition model is obtained by taking a YOLOv5 model as a basic model and lightening model parameters of the YOLOv5 model.
Owner:PEOPLES HOSPITAL PEKING UNIV +2

Isomeric aminophytosphingosines, a method of their production and use

PCT designated stage expiredWO2024258356A1Cosmetic preparationsToilet preparationsD-ribo-phytosphingosinePropizochlor
Stereoselective synthesis of 3,4-diamino-1,2-diols possessing a long hydrocarbon chain was carried out via olefin cross-metathesis between a commercial tetradec-1-ene and known diastereoisomeric trichloroacetamides prepared in our laboratory. Subsequent modification of the obtained coupling products used an approach based on functional group interconversions, which was accompanied by the rational choice of deprotection protocols. The resulting molecules represent novel isomeric amino analogues of natural D-ribo-phytosphingosine, which on the basis of their structure could have the status of skin sphingomimetics, i.e. substances that can affect the properties of the skin and dermis in terms of improving the quality of the lipid matrix (e.g. change in permeability, hydration), or stimulating the biosynthesis of procollagen in deeper structures. The cytotoxic effect of the prepared aminoisophytosphingosines was examined on two human non-malignant cell lines (BJ and HaCaT) and the screening results confirmed the safety in at least three representatives of the prepared series of compounds. In addition, the ability of the synthesized derivatives to inhibit cancer cell proliferation was also investigated. The results of preliminary anticancer screening showed weaker antiproliferative potential of these unusual sphingoid bases.
Owner:UNIVERZITA PAVLA JOZEFA SAFARIKA V KOSICIACH

Gastrointestinal stromal tumor organ culture solution as well as use method and application thereof

The invention discloses a gastrointestinal stromal tumor organ culture solution as well as a use method and application thereof, and belongs to the technical field of gastrointestinal stromal tumor organ culture. The gastrointestinal stromal tumor organs obtained by adopting the culture solution and the culture method provided by the invention can retain histological characteristics and genetic heterogeneity of original tumors of patients, can be used as a medicine sieve model and a disease research model for gastrointestinal stromal tumor treatment, and can promote progressive development of tumor precision medicine; the cultured gastrointestinal stromal tumor organ is high in proliferation speed and cell viability, long-term passage and amplification can be realized, and the gastrointestinal stromal tumor organ with the diameter of more than 100 microns and good activity can be obtained in 8-10 days; the method is also suitable for culturing wild gastrointestinal stromal tumors such as SDH defect type gastrointestinal stromal tumors; the culture medium does not contain components with indefinite components such as serum, is not influenced by different batches, and can maintain relatively high homogenization in the culture process; the cell culture medium can be used for culturing gastrointestinal stromal tumor organs derived from tumor tissues or malignant cell lines of patients, and is suitable for drug sensitivity detection.
Owner:FUJIAN RUIGENG BIOTECHNOLOGY CO LTD

Method for in-situ detection of multiple lung cancer related markers and tumor heterogeneity in living circulating malignant cells

The invention relates to the technical field of biomedicine, in particular to a method for in-situ detection of multiple lung cancer related markers in living circulating malignant cells and tumor heterogeneity. The lung cancer targeted nanoprobe loaded with multiple molecular beacons is used for accurately detecting at least one nucleic acid marker related to the lung cancer in living lung cancer cells, and the levels of different markers in the lung cancer cells are reflected from the single cell level, so that the tumor heterogeneity state of a specific patient is reflected. The nano-probe is a nano-particle self-assembled by a high polymer material, electropositive protein, functional polypeptide and / or functional aptamer, and a molecular beacon of a lung cancer related marker. The nano-probe can target circulating malignant cells with different phenotypes in whole blood, simultaneously detect multiple nucleic acid markers in living cells, and reflect the levels of different markers in the malignant cells from the single cell level, so that the tumor heterogeneity state of a specific patient is reflected, and early accurate diagnosis of lung cancer is realized.
Owner:WUHAN UNIV

Targeted gene integration of NK inhibitors genes for improved immune cells therapy

The invention pertains to the field of adaptive cell immunotherapy. It provides with the genetic insertion of exogenous coding sequence(s) that help the immune cells to direct their immune response against infected or malignant cells. These exogenous coding sequences are more particularly inserted under the transcriptional control of endogenous gene promoters that are sensitive to immune cells activation. Such method allows the production of safer immune primary cells of higher therapeutic potential.
Owner:CELLECTIS SA

Anti-viral and anti-tumoral compounds

Disclosed herein are prokaryotic homologs of viperin (pVips), and nucleotide and nucleoside analogs produced from pVips. These nucleotide and nucleoside analogs stop nucleotide chain synthesis and provide host cells with resistance to viral infections by targeting actively replicating viral genome. Further, these nucleotide and nucleoside analogs decrease DNA replication in malignant cells. Further disclosed are methods of identifying pVips, and nucleotide and nucleoside analogs produced thereof.
Owner:YEDA RES & DEV CO LTD

Precise identification method for benign and malignant cells based on multi-dimensional characteristics of single cell transcriptome

The invention discloses a method for accurately identifying benign and malignant cells based on multi-dimensional characteristics of a single cell transcriptome, and belongs to the technical fields of bioinformatics, tumor molecular biology and cell identification. On the basis of single cell transcriptome sequencing data of tumor tissues and para-carcinoma tissues, three types of information including copy number variation, allele specific copy number variation and tumor-related transcriptional characteristics are synthesized, and final benign and malignant identification is performed on each EpCAM positive epithelial cell through a multi-evidence voting strategy. The method disclosed by the invention has relatively high stability and accuracy in a multi-patient, multi-sample and early tumor scene, particularly improves the recognition capability of early lesion and malignant cells in benign and malignant boundary transition state cells, and provides a reliable technical means for precise diagnosis and individualized treatment of tumors.
Owner:BEIJING INSTITUTE OF GENOMICS CHINESE ACADEMY OF SCIENCES (CHINA NATIONAL CENTER FOR BIOINFORMATION)

Pathological diagnosis support device, pathological diagnosis support method, and pathological diagnosis support program

A pathological diagnosis support device comprises: an acquisition unit that acquires pathological images including cells as subjects; a determination unit that determines whether malignant cells are included in the pathological images by inputting the pathological images to a machine-trained first classification model; a classification unit that classifies the pathological images by class by inputting the pathological images to a second classification model machine-trained to classify the pathological image into any of a plurality of classes including one or more features suggesting the presence of malignant cells; and an output unit that outputs a classification result and supports a user's decision making.
Owner:NEC CORP

Multisomic pathological analysis system and method for predicting risk of colorectal cancer liver metastasis

The application discloses a multi-omics pathological analysis system and method for predicting the risk of colorectal liver metastasis, relates to the technical field of biomedical and cancer diagnosis, and comprises a data acquisition module, a data preprocessing module, a cell analysis module, a score construction module, a model construction and training module and a prediction and evaluation module; the application realizes comprehensive and accurate prediction of the risk of colorectal liver metastasis by integrating multi-omics data, including single-cell data sets, spatial transcriptome data, batch RNA-seq data, clinical data and whole slide image WSIs; the cross-dimension data fusion and analysis not only improve the accuracy and reliability of prediction, but also provide a powerful tool for in-depth exploration of the molecular mechanism of tumor occurrence, development and metastasis, especially in the cell analysis module, identification and analysis of the malignant cell subpopulation LMTMCs triggering liver metastasis can reveal cell subtypes and molecular characteristics closely related to liver metastasis, thereby providing a scientific basis for formulating a personalized treatment plan.
Owner:SOUTHWEST MEDICAL UNIV

Bispecific GPC3xCD28 and GPC3xCD3 antibodies and combinations thereof for targeted killing of GPC3-positive malignant cells

The present invention relates to a GPC3xCD3 bispecific antibody, a GPC3xCD28 bispecific antibody, and a combination of two agonistic fully human κλ antibodies, one targeting GPC3xCD3 and the other targeting GPC3xCD28, both of which do not compete for binding to GPC3. The present invention also relates to the use of the bispecific antibodies for the treatment of GPC3-positive malignancies.
Owner:ラムキャップ バイオ ガンマ エージー

A method for culturing a mucinous pancreatic cystic tumor organoid, a detection method and system

The application belongs to the technical field of medicine, and discloses a method and system for detecting mucinous pancreatic cystic tumor, acquires a pancreatic cyst fluid sample; performs organoid culture on the pancreatic cyst fluid to obtain a mucinous pancreatic cystic tumor organoid; acquires cell morphology data of the mucinous pancreatic cystic tumor organoid; acquires H&E staining data and IHC detection data of the mucinous pancreatic cystic tumor organoid; acquires immunofluorescence detection data of the mucinous pancreatic cystic tumor organoid; performs scRNA-Seq sequencing on the mucinous pancreatic cystic tumor organoid to complete detection of the mucinous pancreatic cystic tumor; and the method can efficiently culture organoids and be used for verifying potential existence of malignant cells in function.
Owner:SHANGHAI ONETAR BIOMEDICINE CO LTD

Compositions and methods for targeting CD33-expressing cancers

Disclosed are compositions and methods for targeted treatment of CD33-expressing cancers. In particular, chimeric antigen receptor (CAR) polypeptides are disclosed that can be used with adoptive cell transfer to target and kill CD33-expressing cancers. Also disclosed are immune effector cells, such as T cells or Natural Killer (NK) cells, that are engineered to express these CARs. Therefore, also disclosed are methods of providing an anti-tumor immunity in a subject with a CD33-expressing cancer that involves adoptive transfer of the disclosed immune effector cells engineered to express the disclosed CARs. Also disclosed are multivalent antibodies that are able to engage T-cells to destroy CD33-expressing malignant cells.
Owner:H LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE INC

Pulsed Low Frequency Magnetic Fields And Tumor Membrane Disruption

Tumor glycocalyx may be regarded as a glycan “canopy” above the tumor plasma membrane. Disclosed are methods of treating a neoplastic malignant cell cancer wherein the neoplastic malignant cancer cell has a malignant glycocalyx B. Also disclosed are methods of inducing apoptosis of one or more neoplastic malignant cells and methods of increasing a subject's responsiveness to an immunotherapy wherein the neoplastic malignant cancer cell has a malignant glycocalyx B.
Owner:THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPT OF VETERANS AFFAIRS

Chimeric antigen receptor exosome of targeted CD8 T cell, CAR-T cell and construction method and application of chimeric antigen receptor exosome

The invention discloses a chimeric antigen receptor exosome targeting a CD8T cell, a CAR-T cell and a construction method and application of the chimeric antigen receptor exosome, and relates to the technical field of biomedicine, and the construction method comprises the following steps: co-transfecting three plasmids, namely BRD-PTK-CD8 < + >-Lamp2b, pcDNA3.1-CD63-L7Ae and pcDNA3.1-N6 (SP)-Nb60-T20-C / D box, into a 293F cell, incubating, and purifying to obtain the exosome capable of targeting the CD8T cell. The exosome can deliver CAR-mRNA to T cells and convert CD8 + cells into CAR-T cells, and blood of an infected person does not need to be drawn; cAR molecules aiming at in-vivo malignant cells can be prepared in vivo; chemotherapy and radiotherapy are not needed, and side effects are avoided; and universality is achieved.
Owner:WUHAN UNIV OF SCI & TECH

Cancer treatment using bosentan in combination with checkpoint inhibitors

This invention provides a combination therapy method to increase the effectiveness of cancer immunotherapy. [Solution] The present invention provides a combination therapy using bosentan and a checkpoint inhibitor that is effective in treating cancer in a target or inhibiting the proliferation of tumor cells, and / or can induce, enhance, or prolong an immune response against tumor cells. The effectiveness of cancer immunotherapy depends on whether T cells can migrate to the tumor, travel to locations adjacent to malignant cells, recognize them, and kill them.
Owner:MATERIA THERAPEUTICS INC +1

BAFF-r bispecific t-cell engager antibody

To provide new therapeutic antibodies against an alternative specific target on malignant cells, and a method of treating cancer and an autoimmune disease.SOLUTION: Provided herein are recombinant proteins (e.g., a bispecific antibody) capable of binding BAFF-R. The recombinant proteins (e.g., bispecific antibody) provided herein are, inter alia, useful for the treatment of cancer and autoimmune disease.SELECTED DRAWING: Figure 4
Owner:CITY OF HOPE

Gene signature for breast cancer margin status after surgery

Positive surgical margins after surgery for breast cancer are defined as malignant cells identified at the edge of the resection specimen and have been associated with at least two-fold increase in ipsilateral breast cancer recurrence, higher distant recurrence rates, and shorter survival. While there have been several clinical factors associated with the risk of positive margins, there is a paucity of data considering both clinical variables and genomic profiles associated with positive margins. In this disclosure was explored the association of clinicopathologic and molecular factors with the occurrence of positive margins after first surgery in breast cancer. As a result, it was found that the occurrence of positive margins after surgery was associated with various clinical factors. Further, as the first effort to pursue molecular understanding of the margin status, a gene panel of 29 genes including 17 protein-coding genes was also identified for potential prediction of the margin status.
Owner:UNIFORMED SERVICES UNIV OF THE HEALTH SCI +2

Antibodies specific for CD38 and uses thereof

CD38 is also expressed in a variety of hematological malignancies, including multiple myeloma. In the present invention, the inventors obtained a new antibody against CD38 that can be used to produce bispecific antibodies and CAR T cell populations. In particular, the inventors reported the development of Bi38-3, a new bispecific T cell engager that targets CD38 on MM cells and forms cytotoxic T cells through CD3ε. Bi38-3 lacks the Fc region of natural mAbs, which contributes to the resistance process, but triggers T cell proliferation, cytokine release, and lysis of CD38-positive MM cells in vitro. Similarly, Bi38-3 induces autologous T cells to eliminate tumor plasma cells isolated from MM patients at diagnosis and relapse. The cytotoxicity triggered by Bi38-3 is limited to cells expressing high levels of CD38 and maintains the integrity of T, B, and NK lymphocytes in vitro. Importantly, Bi38-3 rapidly reduced tumor cells in the MM1.S xenograft mouse model of human MM. In summary, the results show that the antibody of the present invention is an effective agent for specifically eliminating CD38-positive malignant cells without significantly affecting CD38-low-expressing cells, and is a promising new immunotherapy tool for treating malignant blood diseases, especially multiple myeloma.
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +1

Chimeric checkpoint receptors for use in the treatment of malignant B-cell disorders

The present invention relates to chimeric checkpoint receptor (CCR) fusion proteins, nucleic acid molecules encoding said fusion proteins, vectors comprising said nucleic acid molecules, host cells comprising said nucleic acid molecules and / or expressing said fusion proteins, methods of providing said host cells, pharmaceutical compositions comprising said fusion proteins, nucleic acid molecules or host cells, and said products for use as medicaments and in the treatment of B-cell lymphoma.
Owner:UNIVERSITY OF COLOGNE

Method for transduction of t cells in the presence of malignant cells

The present invention provides an in-vitro method of reducing the efficiency of transducing malignant cells of the blood system of a subject that are not derived from T cells with lentiviral vector particles without reducing the efficiency of transducing T cells in a sample comprising T cells and said malignant cells. A combination of compositions comprising a first composition and a second composition is also disclosed, wherein said first composition comprises i) transduced T cells of a subject, wherein said transduced T cells express a CAR comprising an antigen binding domain, wherein the antigen binding domain of said CAR binds specifically to a tag of a tagged polypeptide, and ii) non-transduced malignant cells of the blood system of said subject, and wherein said second composition comprises said tagged polypeptide, wherein said tagged polypeptide binds specifically to an antigen expressed on the surface of said malignant cells. Alternatively, the transduced T cells of said first composition may comprise a nucleic acid encoding a CAR and an inducible gene expression system, and said second composition may comprise an induction agent inducing said gene system.
Owner:MILTENYI BIOTEC BV & CO KG

Treatment of cancer and inhibition of metastasis

Compounds and methods are disclosed for reducing or preventing metastatic behaviour in VGSC expressing cancer by the effect of at least reducing the persistent part of the voltage gated sodium channel current without eliminating the transient part, thereby inhibiting the metastatic and invasive growth of malignant cells in a cancer patient.
Owner:CELEX ONCOLOGY INNOVATIONS LTD

Application of combination of ZNF496 protein and KDM2B protein in medicine for treating cervical cancer

The invention belongs to the field of biological medicines, and particularly relates to application of a combination of ZNF496 protein and KDM2B protein in a medicine for treating cervical cancer. According to the invention, the interaction relationship of the ZNF496 protein and the interaction protein KDM2B thereof is proved for the first time, the inhibition effect of the combination of the ZNF496 protein and the interaction protein KDM2B thereof on an NF-kappa B pathway in cervical cancer cells is provided for the first time, and the application of the ZNF496 protein and the interaction protein KDM2B thereof in inhibiting malignant cell biological behaviors of the cervical cancer cells is provided for the first time. By means of the mechanism, a specific targeted therapy scheme can be designed, and the specific targeted therapy scheme is applied to preparation of ZNF496 and KDM2B combined overexpression preparation drugs and implementation of accurate individualized treatment on cervical cancer patients and has important application prospects in clinical treatment.
Owner:ACADEMY OF MILITARY MEDICAL SCIENCES +1

Pancreatic cancer dependency gene scoring prognosis model construction method based on multi-algorithm optimization

The invention relates to the field of biomedicine, and discloses a pancreatic cancer dependency gene score prognosis model construction method based on multi-algorithm optimization, which can utilize a machine learning algorithm to identify biomarkers related to pancreatic cancer prognosis and survival, construct a prognosis model and improve the prognosis accuracy. Comprising the following steps: identifying the activity of pancreatic cancer malignant cells and pancreatic cancer dependent genes; identifying a PADG subgroup by consistent clustering; constructing a prognosis model; performing prognosis gene correlation analysis; the invention relates to machine learning prognosis model immunotherapy assessment based on pancreatic cancer dependent gene scoring. The kit has the advantage that the risk and prognosis of the pancreatic cancer patient receiving immunotherapy can be accurately predicted. The treatment effect is improved, and the lifetime of a patient is prolonged. Discovery of a new treatment target is facilitated, and development of the pancreatic cancer treatment field is promoted.
Owner:GENERAL HOSPITAL OF THE NORTHERN WAR ZONE OF THE CHINESE PEOPLES LIBERATION ARMY